Polymethylmethacrylate strengthens antibody response in hemodialysis patients not responding to hepatitis B vaccine: Preliminary data

Minerva Medica

Volumn 102, Issue 6, 2011, Pages 469-474

  Duranti, E ^a   Duranti, D ^a  

^a San Sepolcro Hospital   (Italy)

Author keywords

Hepatitis B vaccines; Polymethyl methacrylate; Uremia

Indexed keywords

BICARBONATE; CD40 ANTIGEN; HEPATITIS B ANTIBODY; HEPATITIS B VACCINE; POLY(METHYL METHACRYLATE); POLYACRYLONITRILE; POLYAMIDE; POLYSULFONE; RECOMBINANT HEPATITIS B VACCINE;

ADULT; AGED; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; ARTIFICIAL KIDNEY; CLINICAL ARTICLE; DIALYSIS MEMBRANE; FEMALE; HEMODIALYSIS; HUMAN; IMMUNOCOMPETENCE; MALE; REVACCINATION; TREATMENT OUTCOME; UREMIA; VACCINATION;

ADSORPTION; AGED; ANTIGENS, CD40; FEMALE; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION, SECONDARY; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PILOT PROJECTS; POLYMETHYL METHACRYLATE; RENAL DIALYSIS; VACCINES, SYNTHETIC;

EID: 84857559080     PISSN: 00264806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Higgins RM. Infections in a Renal Unit. QJ Med 1989;70:41-51. (Pubitemid 19083971)
2. Crosnier J, Jungers P, Couroucé AM, Laplanche A, Benhamou E, Degos F et al. Randomised placebo-controlled trial of hepatitis B surface antigen vaccine in French hemodialysis units. Lancet 1981;1:797-800. (Pubitemid 11147433)
3. Köhler H, Arnold W, Renschin G, Dormeyer HH, Meyer zum Büschenfelde KH. Active hepatitis B vaccination of dialysis patients and medical staff. Kidney Int 1984;25:124-8.
4. Descamps-Latscha B, Chatenoud L. T cells and B cells in chronic renal failure. Semin Nephrol 1996;16:183-91. (Pubitemid 26151233)
5. Durie FH, Foy TM, Masters SR, Laman JD, Noelle RJ. The role of CD40 in the regulation of humoral and cell-mediated immunity. Immunol Today 1994;15:406-11. (Pubitemid 24272184)
6. Schwabe RF, Engelmann H, Hess S, Fricke H. Soluble CD40 in the serum of healthy donors, patients with chronic renal failure, haemodialysis and CAPD patients. Clin Exp Immunol 1999;117:153-8. (Pubitemid 29292791)
7. Ronco C, Brendolan A, Lonnemann G, Bellomo R, Piccinni P, Digito A et al. A pilot study of coupled plasma filtration with adsorption in septic shock. Crit Care Med 2002;30:1250-5. (Pubitemid 34620967)
8. Cruz DN, Antonelli M, Fumagalli R, Foltran F, Brienza N, Donati A et al. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA 2009;301:2445-52.
9. Contin C, Pitard V, Delmas Y, Pelletier N, Defrance T, Moreau JF et al. Potential role of soluble CD40 in the humoral immune responce impairment of uraemic patients. Immunology 2003;110:131-40. (Pubitemid 37059681)
10. Perrone B. Serendipity: a necessity for the progress of dialysis therapy. Nephrol Dial Transplant 2007;22(Suppl 5):v37-v8.
11. Contin C, Pitard V, Delmas Y, Pelletier N, Defrance T, Moreau JF et al. Potential role of the soluble form of CD40 in deficient immunological function of dialysis patients: new findings of its amelioration using polymethylmethacrylate (PMMA) membrane. Nephrol Dial Transplant 2010;3(Suppl 1):i20-i7.
12. Centers for Disease Control and Prevention, Atlanta. Update US Public Health Service Guidelines for management of occupational exposures to HBV,HCV and HIV and recommendations for post exposure Prophylaxis. MMWR 2001;50(n. RR-11).
13. Girndt M, Sester M, Sester U, Kaul H, Köhler H. Defective expression of B7-2(CD86) on monocytes of dialysis patients correlates to the uremia-associated immune defect. Kidney Int 2001;59:1382-9. (Pubitemid 32281226)
14. Kuroki Y, Tsuchida K, Go I, Aoyama M, Naganuma T, Takemoto Y et al. A study of innate immunity in patients with end - stage renal disease: special reference to toll-like receptor-2 and -4 expression in peripheral blood monocytes of hemodialysis patients, Int J Mol Med 2007;19:783-90.
15. Ishikawa I, Chikazawa Y, Sato K, Nakagawa M, Imamura H, Hayama S et al. Proteomic analysis of serum, outflow dialysate and adsorbed protein onto dialysis membranes (polysulfone and PMMA) during hemodialysis treatment using SEL-DI-TOF-MS. Am J Nephrol 2006;26:372-80. (Pubitemid 44394156)
16. Aoike I. Clinical significance of protein adsorbable membranes-long-term clinical effects and analysis using a proteomic technique. Nephrol Dial Transplant 2007;22:v13-v19.
17. Gagiong ZM. Inhibition of immunoglobulin production by parathyroid hormone. Implications in chronic renal failure. Kidney Int 1991;40:96-106.
18. Gaciong Z, Alexiewicz JM, Massry SG. Impaired in vivo antibody production in CRF rats: role of secondary hyperparathyroidism. Kidney Int 1991;40:862-7.
19. Esposito P, Gabanti E, Sepe V, Rampino T, Magrassi A, Albizio B et al. 109 CO - Pathway CD40. In: Hemodialisys. G Ital Nefrol 2010;27(S51):S28-S63.
20. Biasioli S, Schiavon R, Petrosino L, Cavallini L, Cavalcanti G, De Fanti E. Role of cellulosic and non-cellulosic membranes in hyperhomocysteinemia and oxidative stress. ASAIO J 2000;46:625-34.
21. Tessitore N, Lapolla A, Aricò NC, Poli A, Gammaro L, Bassi A et al. Effect of protein leaking BK-F PMMA-based hemodialysis on plasma pentosidine levels. J Nephrol 2004;17:707-14. (Pubitemid 40484585)
22. Yamada S. Isolation of mast cell degranulation factor from dialysis patients with pruritus and its removal by dialysis membrane. Kidney And Dialysis 2003,55(Supp.):167-71.
23. Contin C, Pitard V, Itai T, Nagata S, Moreau JF, Déchanet-Merville J. Membrane-anchored CD40 is processed by the tumor necrosis factor-a-converting enzyme. J Biol Chem 2003;278:32801-9. (Pubitemid 37055721)
24. Campistol JM, Torregrosa JV, Ponz E, Fenollosa B. Beta2-microglobulin removal by hemodialysis with polymetilmetacrylate membranes. Contrib Neprhol 1999;125;76-85.
25. Kawanishi H. Intensive and critical care medicine 12 s7-s8, Proceedings 2000.
26. Abel JJ, Rowntree LG, Turner BB, Akizawa T, Kinugasa E, Sato Y et al. Chronic inflammation in hemodialysis: the role of contaminated dialysate. Blood Purif 2000;18:214-23.
27. Colin AH, Cook M, Heyne N, Weisel K, Billingham L, Bradwell A et al. Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies. J Am Soc Nephrol 2007;18:886-95. (Pubitemid 46434505)
28. Oshihara W, Megano H, Arai J, Takada M. Trial use of a polymethylmethacrylate membrane for the removal of free immunoglobulin light chains in dialysis patients. NDT plus 2010;3(S1):13-7.
29. Clark WR, Gao D. Low-molecular weight proteins in end-stage renal disease potential toxicity and dialysis removal mechanism. J Am Soc Nephrol 2002;13(Suppl1):S41-S7.
30. Lee WC, Uchino S, Fealy N, Baldwin I, Panagiotopoulos S, Goehl H et al. Super high-flux hemodialysis at high dialysate flows: An ex vivo assessment. In J Artif Organs 2004;27:24-8. (Pubitemid 38268260)
31. Galli F, Benedetti S, Buoncristiani U, Piroddi M, Conte C, Canestrari F et al. The effect of PMMA-based protein-leaking dialyzers on plasma homocysteine levels. Kidney International 2003,64:748-55. (Pubitemid 36871951)
32. Pawlak K, Mysliwiec M, Pawlak D. Hepatitis C virus seropositivity and TNF superfamily receptors: sCD40, sFas-the new putative determinants of endothelial dysfunction in hemodialysis patients. Thrombosis Research 2010;126:393-8.